Podcasts about Nephrology

Dietary Approach To Kidney Disease Join us as Dr. Sean Hashmi, an experienced nephrologist and lifestyle medicine specialist, delves deep into the dietary approach to managing kidney diseases. He provides an engaging discussion, debunking common diet myths, and highlighting the importance of a balanced, plant-based diet and the impact of lifestyle choices on kidney health. This video is a must-watch for those seeking a comprehensive understanding of kidney health from a dietary perspective. #KidneyHealth #DietaryApproach #DrSeanHashmi Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Medical missionaries from Western industrialized nations frequently encounter ethically disturbing situations when providing care in the developing world. This may be due to generally-recognized ethical principles being largely influenced by Western realities, beliefs and values. Individuals in resource-limited settings may have very different views on the risks and benefits of medical care, widely disparate access to reliable treatment, and decision-making that emphasizes honoring the opinions of the group over those of the individual. After briefly reviewing some basic tenets of medical ethics, this session will work through a number of actual cases with the goal of finding potential ways forward in each.

CME credits: 0.25 Valid until: 17-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/hyperkalemia-in-ckd-and-hfrefwhat-am-i-missing/15320/ Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It's especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.=

A class of drugs called glucagon-like peptide agonists (GLP-1 agonists) is proving to be beneficial for people with chronic kidney disease and atherosclerotic heart disease. These medications are being called game changers because they not only help with weight loss but also provide organ protection and reduce the risk of dying and disease progression. These medications have the potential to revolutionize the treatment of deadly conditions and improve population health. However, there are financial pressures and healthcare policies that may hinder access to these medications for patients who could benefit from them. On today's program, host Sean Collins talks with two Physician-Researchers working on the front lines of the coming change...Katherine R. Tuttle, M.D., FASN, FACP, FNKFExecutive Director for Research, Providence Inland Northwest HealthProfessor of Medicine, Division of Nephrology and Kidney Research InstituteRegional Principal Investigator, Institute of Translational Health SciencesUniversity of Washington.Radica Alicic, M.D., FHM, FACPAssociate Director for ResearchProvidence Health Care in Spokane..Management of Chronic Kidney Disease in People with Diabetes Read more about Retatrutide, the triple agonist 

A nephrologist for over 35 years, Vivek Jha discusses kidney function and disease treatments like dialysis and kidney transplantation. He helps listeners understand Ties between kidney function and most other organ systems, Differences between acute and chronic kidney disease, and Efforts towards bringing disadvantaged communities the best in kidney disease treatments. Vivekanand Jha is Executive Director at The George Institute for Global Health, India; Chair of Global Kidney Health, Faculty of Medicine, Imperial College of London; and President of the International Society of Nephrology. online pharmacy buy temovate over the counter online pharmacy In this podcast he covers the basics of kidney function, kidney disease, and late-stage efforts like dialysis treatment. He accompanies all these issues with an eye to the global inequalities in effective treatment and discusses ways to educate populations and bring better medicine to all. online pharmacy buy synthroid over the counter online pharmacy In fact, he tells listeners that he became a nephrologist partly because of these inequalities. He also describes why the biology intrigued him: kidney function presents a "microcosm of internalized medicine. online pharmacy buy wellbutrin over the counter online pharmacy " In other words, the kidney affects all other organs and, as a doctor, one utilizes every element of internalized medicine to address kidney issues.  He describes the complex and essential nature of kidney functions, from filtration, adaptability to different solutes, hormone production, and the biology behind these jobs such as nephrons function. He teaches listeners about the back and forth between kidneys and blood pressure control and talks about how early stage kidney disease is usually symptomless. He advises listeners on which tests to seek out regularly for those at risk and touches on the goal of dialysis treatment. Finally, he talks more about the necessity for policy changes by governments in addressing health disparities in a holistic manner. For more about global kidney health, see the International Society of Nephrology website, theisn.org, and for more about his team's research, see his page at The George Institute for Global Health: georgeinstitute.org/people/vivekanand-jha. Available on Apple Podcasts: apple.co/2Os0myK

CME credits: 0.25 Valid until: 03-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-the-evidence-from-iv-iron-trials-in-heart-failure/15334/ Iron deficiency is an independent predictor of decreased functional capacity and reduced survival in our patients with heart failure. Multiple clinical trials have addressed the issue, but we continue to struggle with the clinical implications of the data. Join Drs. Stefan Anker, Robert Mentz, and Piotr Ponikowski as they discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for your practice and patients. =

While chronic kidney disease diagnosis is rare in children, its effects are profound. Furthermore, there's so much scientists don't know about kidney function. Keia Sanderson is hoping to change that. She specializes in chronic kidney disease treatment in pediatric patients and discusses avenues to advance treatment and prevention. This podcast gives her the perfect platform to explain How kidney disease is especially challenging to identity in children because chronic kidney disease stages are often asymptomatic in pediatric patients, Why preterm babies are vulnerable to certain conditions because of the development timing of the nephrons, and Why it's important to identity intervention measures before dialysis and kidney transplantation provide the only recourse. Keia Sanderson, MD, is an assistant professor of medicine in the Division of Nephrology and Hypertension at the University of North Carolina School of Medicine. Her job is a mix of teaching, clinical work, and research. In her clinical work, she takes care of children with kidney disease at all stages, including kids who receive transplants. Her current research is focused on kidney outcomes in children with complex medical histories, in particular children who've been born prematurely. She says that the challenge is oftentimes the asymptomatic nature of kidney disease in children. Therefore, she and other clinicians are often meeting kids with disease states that are irreversible and are turning toward dialysis treatment and transplantation.  Dr. Sanderson gives listeners a special focus on the risks from preterm birth. Because preterm babies tend to have less nephron development, the nephrons that are present have to work overtime and are subject to hyper filtration. But because doctors have been able to identify this as a critical time, they are looking at ways to better manage preterm infant treatment. For example, what medications are they receiving that could affect kidney development? How are we feeding infants in this active development stage? How are we handling their oxygenation? While a clear pathway is not yet evident, she is hopeful she and other researches will find one. Currently, she's hoping to develop mathematical models to make better predications about the risk levels for different babies. For more information, see the UNC Kidney Center, the National Kidney Foundation, and talk to your primary doctor. Available on Apple Podcasts: apple.co/2Os0myK 

Dr. Staci Leisman is a board certified internist and nephrologist who practices nephrology at Mount Sinai Hospital. She is also an accomplished educator in the Icahn School of Medicine at Mount Sinai. 
Dr. Leisman received her B.A. in English Language and Literature from Yale University, where she graduated magna cum laude and was inducted into Phi Beta Kappa. She received her M.D. from Washington University in St Louis, where she was one of 8 recipients of the Distinguished Scholar Award. She completed her residency in Internal Medicine and fellowship in Nephrology at Mount Sinai Medical Center. As a fellow, she completed research in transplant immunology in the laboratory of Dr. Peter Heeger, which resulted in a Young Investigator Award from the American Society of Transplantation and two oral presentations at the American Transplant Congress. During her fellowship, she co-first authored and was a contributing author on numerous papers. 
Dr. Leisman's clinical duties include caring for patients on dialysis at an outpatient dialysis facility, as well as attending on the inpatient renal service at Mount Sinai Hospital. 
Dr. Leisman has been extensively involved in teaching throughout her career. She currently teaches students at all levels of medical education, including medical students, residents and fellows.  She is the course director for the Human Physiology course in the medical school, and holds a secondary appointment in the Department of Medical Education, where she is a co-director for the medical school curriculum. In her capacity as an educator, she has won numerous awards including Teacher of the Year at North General Hospital, the Edward Ronan Student Council Award at the Icahn School of Medicine, the Institute for Medical Education's Excellence in Teaching Award, the Student Council Lifetime Achievement Award, the JOWMA Outstanding Achievement Award, and the Gold Humanism in Medicine Award. She has been selected for membership in the Institute for Medical Education as a Master Educator. 
Dr. Leisman also serves on the International Association of Medical Science Educators' educational scholarship committee, and serves on the editorial board of Advances in Chronic Kidney Disease, the Journal of the National Kidney Foundation. She is the Deputy Education Director for the Kidney Self Assessment Program (KSAP), the preeminent board preparation tool published by the American Society of Nephrology. _______________________________________________________ Become a JOWMA Member! www.jowma.org  Follow us on Instagram! www.instagram.com/JOWMA_org  Follow us on Twitter! www.twitter.com/JOWMA_med  Follow us on Facebook! https://www.facebook.com/JOWMAorg/ Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

An implantable bioartificial kidney system that does what dialysis can't do; this is what's being developed as part of The Kidney Project at University of California, San Francisco and Vanderbilt University. Press play to learn: How healthy kidneys function, and what dialysis does What causes the symptoms associated with advanced kidney failure What to consider in terms of the tradeoff between a kidney transplant and the need for immunosuppressants, and a bioartificial kidney and no need for immunosuppressants Lynda Frassetto is Professor Emeritus of Medicine in the Division of Nephrology at the University of California, San Francisco. She spends some of her time taking care of nephrology patients, and some of her time working with William Fissell, MD and Shuvo Roy, PhD, who lead The Kidney Project. Dialysis can keep patients alive by filtering toxins out of the blood, which is what healthy kidneys do. But what happens to the fluid after it's been filtered? In healthy bodies, the fluid goes through kidney tubules, where it responds to chemical signals which might dictate that more water or salt be resorbed, and/or that more creatinine, phosphorus, urea, or other acids be removed. After the toxins have been filtered, the fluid is subjected to the feedback systems of the body, which is essential to keeping the body's water and chemical levels where they should be. This is something that dialysis simply cannot accomplish, but it's not too great a task for the artificial system being created; this system has renal tubular cells, so it can keep the body's water and chemistry levels in check, which translates to better quality of life for patients. Press play for the details of all this and more, including where in the body it is placed, how it stacks up against transplanted kidneys in terms of normal kidney function, when it might receive FDA approval for testing in humans, and what the first clinical trials will look like. Available on Apple Podcasts: apple.co/2Os0myK

Iman speaks with Dr. Gerald Da Roza, an internist and nephrologist at UBC. This episode is jammed packed with gems and pearls of wisdom regarding career decision making, lifestyle in medicine, and considerations when choosing an internal medicine subspecialty. Dr. Da Roza shares his journey to medicine and nephrology while giving very candid advice about being honest with yourself throughout this journey and touching on the comparison game. Regardless of your specialty of interest, this episode is sure to touch on a topic you've been thinking about! Guest: Dr. Gerald Da Roza Hosted and Edited by: Iman LahouaoulaMusic: Dr. Ian DownieLearn more and listen to the family of UBC Medicine Learning Network Podcasts: https://education.med.ubc.ca/ubc-medicine-learning-network-podcasts/Follow the UBC Medicine Learning Network on all social media: @ubcmedvid(C) 2023 UBC Medicine Learning Network

One of the biggest challenges is identifying kidney disease in the early and middle stages, says Prabir Roy-Chaudhury. He works to emphasize the importance of simple blood and urine tests for high-risk populations for earlier diagnosis, but also strives for better treatment once kidney failure sets in. He discusses: Why his main interest is dialysis vascular access dysfunction, What are common issues, such as cardiovascular complications in kidney disease patients, How current tests like the GFR and albumin amounts are calculated and why they determine the kidney failure risk equation, and What should patients prioritize in treatment, from Vitamin D importance to new drugs and technologies. Prabir Roy-Chaudhury is a professor of medicine in the Division of Nephrology and Hypertension and co-director of UNC Kidney Center and specializes in uremic vascular biology. He brings listeners online with the basics of kidney disease, who's at risk, and what's being done to make treatment better. We need our kidneys to rid our bodies of toxic byproducts and fluid, he says. If the kidneys can't rid us of our byproducts, these uremic solutes accumulate in the blood and our systems suffer. That's why doctors turn to other ways of filtrating these out of our bodies through dialysis. That's also where Dr. Roy-Chaudhury would like to see improvement. He explains both types of dialysis—hemodialysis and peritoneal dialysis—describing their strengths and weaknesses. He adds that “my dream definitely would be for us to be in a slightly different place” with dialysis. He shares some good news towards that end: that the American Society of Nephrology has partnered with the FDA and Health and Human Services to produce public and private partnerships, such as the Kidney Health Initiative and the Kidney Innovation Accelerator, to improve these treatments. Listen in to learn about these exciting projects that hope to dramatically change the quality of life for patients with kidney disease. Episode also available on Apple Podcasts: apple.co/30PvU9C

Every day healthcare workers face a lot of stressful and emotionally challenging situations at work. Moreover the long drawn pandemic has had its impact on healthcare workers. Numerous deaths, making difficult choices due to resource constraints and overstretched days are some of the challenges that have affected health workers mentally and emotionally. With daily work demands being constant many of them are left with these issues unresolved. How then can we care for our caregivers who support the health and quality of life of their patients and their relatives? This is a taster of a program that uses large group learnings, small group sharing, peer-to-peer interactions and role-plays. This session will also provide an overview of the program that provides healthcare teams a platform to address their unaddressed pain, and emotional as well as psychological hurts Using a structured and sustained approach the program provides the supportive environment, caring community and appropriate skills for the healing of healthcare workers and equips them to go on to become better careers in the workplace. https://bit.ly/gmhc2022_mathewmulavelil_caringforthecaregiver

CME credits: 1.00 Valid until: 24-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/whats-new-about-gout-nephrology-perspective/15961/ Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients' quality of life.

CME credits: 1.00 Valid until: 24-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/is-managing-gout-in-the-nephrology-clinic-a-challenge/15957/ Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients' quality of life.

CME credits: 1.00 Valid until: 24-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/is-gout-hiding-in-the-nephrology-clinic/15956/ Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients' quality of life.

Clinical trials exist to help prevent, screen for, diagnose, or treat diseases and other health problems. Without them, we would not have new treatments or other advances in health and medicine. But how are the clinical trial endpoints, or the preferred outcomes of these trials determined? Today, Anthony Gucciardo NKF's Senior Vice President of Strategic Partnerships, Dr. Joseph Vassalotti, NKF's Chief Medical Officer, and Kent Bressler, a Patient advocate and FSGS patient, discuss this and more.   In this episode we heard from:  Dr. Joseph Vassalotti MD Dr. Vassalotti is the Chief Medical Officer of the National Kidney Foundation (NKF) and Clinical Professor of Medicine in the Division of Nephrology, at Icahn School of Medicine at Mount Sinai. At NKF, his major focus is implementation of evidence-based clinical practice guidelines in chronic kidney disease (CKD). He led collaborations to develop the Kidney Health Evaluation for Adults with Diabetes quality measure to improve evidenced based estimated glomerular filtration rate and albuminuria testing to guide detection, risk stratification and interventions proportional to risk in the U.S. He also served as PI for an AARP-funded Kidney Health Evaluation for Adults with Diabetes to analyze quality measure satisfaction with detection, evidenced-based therapies and health equity. Currently, he serves as Principal Investigator for the Kidney Score Platform, an NKF educational project funded by the Veterans Administration Center for Innovation to improve awareness and education among Veterans with and at risk for CKD in the primary care setting. He is also a co-investigator for the Center for Disease Control and Prevention's CKD Surveillance Project. Dr. Vassalotti typically sees approximately 40 patients per week and has over 100 publications in peerreviewed journals. Anthony Gucciardo Anthony is responsible for forging and maintaining relations with key external stakeholders across a wide range of industries, to advance NKF's mission and objectives, along with those of its partner organizations.  Anthony oversees two national Corporate Development Teams, focused on securing revenue necessary to ensure NKF programmatic excellence and impact.  He has been with the Foundation since 2002. Prior to NKF, Anthony was a Hematopoietic Stem Cell Technologist at Memorial Sloan-Kettering Cancer Center in New York City, where he was responsible for processing autogeneic/allogeneic bone marrow and peripheral blood stem cells for transplantation. He holds a master's degree in Biochemistry from Columbia University. Kent Bressler Kent is a retired RN who was diagnosed with FSGS in 1984, and received a living donor transplant from his brother Kip in 1987. Kent is an active advocate for preemptive kidney transplant and has on the recommendation of NKF worked closely with the DoD and PCORI as a consumer peer reviewer. He is an NKF peer mentor and advocate who has collaborated on an editorial “Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease,” published in AJKD in 2019. He will also be participating in the development of the new NKF Patient Network serving on the Data Input and Integration Committee. He has been an active hill advocate for the NKF for six years and was the proud recipient of the 2017 Richard K. Salick Advocacy Award. Kent is also an Army Veteran and retired from the Veterans administration as an RN. He is the co-founder of Kidney Solutions a not for profit program in Texas that assists patients and families in the transplant process and in finding a donor. He is currently an assistant team leader for Region 7. Kent and Cathy Bressler have been married for 50 years and their family consists of Gretchen and Todd Rossington and their son Colt and Celeste and Alex Brown and their children John Banks, Catherine and Alexis Brown.   Additional Resources:  Find Clinical Trials  Clinical Trial Q&A  Xenotransplantation Info    Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

CME credits: 0.25 Valid until: 20-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/2023-esc-guideline-updates-where-are-we-with-iron-deficiency/15330/ Clinical trials provide evidence to support guideline recommendations. What's changed with the recommendations for iron deficiency in heart failure? Watch as experts Giuseppe Rosano, MD, Marco Metra, MD, and Gianluigi Savarese, MD discuss the recent updates to the ESC guidelines, including the latest clinical trial evidence, and the expanded use of IV iron in iron deficient heart failure patients.=

CME credits: 0.50 Valid until: 18-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-practical-look-at-cardiorenal-protection-for-ckd-in-t2d-applying-recent-data/14594/ Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.=

CME credits: 0.25 Valid until: 19-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-mitigating-health-disparities-in-patients-with-anemia-of-ckd/16090/ In this microlearning module, Dr. Ajay Singh, Nephrologist in the Renal Division at Brigham and Women's Hospital in Boston, discusses health disparities in patients with anemia of CKD and strategies to mitigate them. =

Evidence based medicine is emphasized worldwide. An important skill in the practice of evidence based health care is the ability to critically appraise the validity of published literature. This lecture will explore principles of evidence based medicine and critical appraisal of randomized controlled trial.

CME credits: 0.25 Valid until: 09-10-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-multidisciplinary-approach-to-managing-potassium-levels-in-patients-with-heart-failure-when-optimizing-raasi-therapy-in-complex-cases/15325/ Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.=

Mentors are instrumental in the professional and personal growth of healthcare professionals. However, mentoring relationships often fail to realize their full potential. Attendees will be encouraged and equipped to initiate mentoring relationships that provide both mentor and mentee with a rewarding experience.

CME credits: 0.25 Valid until: 15-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/emerging-treatment-for-anemia-of-ckd-hif-ph-inhibitors/16089/ In this activity, Dr. Jay Wish, Chief Medical Officer for Outpatient Dialysis in the Division of Nephrology at Indiana University Health, discusses emerging treatment for Anemia of chronic kidney disease (CKD), specifically with hypoxia-inducible factor–prolyl hydroxylase domain (HIF-PH) inhibitors.=